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Abstract
Objective: Lamotrigine trial in SPMS was a randomised control trial to assess whether partial blockade of sodium channels
has a neuroprotective effect. The current study was an additional study to investigate the value of neurofilament (NfH) and
other biomarkers in predicting prognosis and/or response to treatment.
Methods: SPMS patients who attended the NHNN or the Royal Free Hospital, UK, eligible for inclusion were invited to
participate in the biomarker study. Primary outcome was whether lamotrigine would significantly reduce detectable serum
NfH at 0-12, 12–24 and 0–24 months compared to placebo. Other serum/plasma and CSF biomarkers were also explored.
Results: Treatment effect by comparing absolute changes in NfH between the lamotrigine and placebo group showed no
difference, however based on serum lamotrigine adherence there was significant decline in NfH (NfH 12–24 months
p = 0.043, Nfh 0–24 months p = 0.023). Serum NfH correlated with disability: walking times, 9-HPT (non-dominant hand),
PASAT, z-score, MSIS-29 (psychological) and EDSS and MRI cerebral atrophy and MTR. Other biomarkers explored in this
study were not found to be significantly associated, aside from that of plasma osteopontin.
Conclusions: The relations between NfH and clinical scores of disability and MRI measures of atrophy and disease burden
support NfH being a potential surrogate endpoint complementing MRI in neuroprotective trials and sample sizes for such
trials are presented here. We did not observe a reduction in NfH levels between the Lamotrigine and placebo arms,
however, the reduction in serum NfH levels based on lamotrigine adherence points to a possible neuroprotective effect of
lamotrigine on axonal degeneration.
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Introduction
Sodium channel blockade is postulated to protect axons from
anoxia-induced injury secondary to neuroinflammation. However,
the Phase II lamotrigine trial in secondary progressive MS
encountered an unexpected result with lamotrigine causing early
cerebral volume loss that partially corrected after discontinuation
of treatment. This effect may have been due in part to reversible
fluid shifts or a reduction in inflammation due to the treatment.
Neurofilament proteins are the scaffolding proteins of neurons
and are markers of neuro-axonal injury [1,2]. CSF neurofilament
(NfH) have been shown to be higher in all sub-types of MS
compared to control subjects and elevated during the active [3] as
well as the progressive phases correlating with clinical scales EDSS
and MSFC [1,4]. NfH is also detectable in the blood but has only
been studied in one retrospective study evaluating response to
interferon-b therapy, with no significant differences between the
responders and the non-responders [5].
The biomarker study was to test whether lamotrigine could
significantly reduce detectable NfH in sera at 12 and 24 months
relative to baseline, compared to placebo. Other hypotheses
explored included whether NfH predicts cerebral and spinal cord
atrophy as measured using MRI and disability scales. A further
exploratory panel of nitrite/nitrate, GFAP, BDNF and NGF NfL,
ferritin, MBP, growth factors NCAM, GAP-43, N-acetylaspartate
(NAA), cytokines CXCL12, BLC, CCL19, CCL21, TNFa, TNFb,
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IFNc, interleukins 2, 4, 5, 6, 8, 10, 12p70, 1b, oxysterols 24OHC/
27OHC, lanosterol and cholesterol, DJ-1, osteopontin, were
measured based on their evidence as biomarkers of disease activity
in MS.
Materials and Methods
Study methodology
120 subjects with SPMS were recruited into the lamotrigine trial
lasting two years (NCT00257855) [6]. Subjects for this study were
recruited from the principle trial and thus the same inclusion/
exclusion criteria applied: age 18–60 years, SPMS with a steady
progression rather than relapse causing disability in the preceding
two years, EDSS 4.0–6.5. Subjects with a rapid deterioration
eligible for alternative treatment, taking Na+ or Ca2+ channel
blockers, or had received immunosuppressive agents recently were
excluded. This study was approved by the University College
London Hospitals Committee and National Research Ethics
Committee; written consent was obtained as outlined by the
ethics committees.
101 subjects were included in the serum biomarker analyses
owing to drop out or missing time points during the course of the
study, and twenty-three underwent lumbar punctures. Lamotri-
gine group was further divided according to their adherence to
treatment based on serum lamotrigine levels and tablet returns (see
Table 1). Power calculations for the study were based on previous
data using NfH, a sample size of 40 subjects in each arm was
required to detect a difference of 30% in the proportion of subjects
with undetectable NfH at 12 months (10% placebo vs 40% on
lamotrigine). The sample size was based on a power of 80% at 5%
significance level, with a combined loss to follow-up and/or non-
compliance of 10%. Further modelling of serum biomarker data
included all available samples (see Table S1). Cerebral volume,
mean cervical spinal cord area, whole brain, grey matter and white
matter magnetisation transfer ratios, and T1 and T2 lesions,
EDSS and MSFC (25-foot timed walk, 9-hole peg test, and paced
auditory serial addition test) were performed in all subjects. The
timing of patient follow-up and investigations are shown in
Figure 1.
Blood and CSF sampling
Blood was collected in Beckton-Dickinson (BD) tubes, centri-
fuged at 2,500 rpm for 10 minutes before aliquoting, CSF was
centrifuged at 1,500 rpm for 5 minutes, cell-free CSF was
aliquoted and stored at 280uC. The first aliquot of CSF and
paired blood sample were processed for microbiology, protein and
CSF/serum oligoclonal bands.
Biomarker analysis
Serum. NfH (#NS170, Millipore; CV 4%, limit of detection/
LOD 2 SD [standard deviations] above the background was
0.14 ng/ml), BDNF (#CYT306, Chemicon; CV 2%, LOD
0.27 ng/ml) and NGF (#CYT304, Chemicon; CV 2%,
0.23 ng/ml) were measured using ELISA kits. NOx was measured
using vanadium assay by Rejdak et al [7] (CV 9%, LOD 0.99 mM/
l). GFAP was measured using ELISA by Petzold et al [8] with
modifications: primary antibody (#SMI-26R, Covance) at 1/
1000, secondary polyclonal rabbit anti-GFAP (#Z033401, Dako)
at 1/1000 and tertiary swine anti-rabbit HRP (#P0217, Dako) at
1/1000, with top standard of GFAP protein starting at 25 ng/ml
(#345996, Calbiochem); CV 8%, LOD 0.22 ng/ml.
Paired CSF/serum/plasma. CSF 24OHC, 27OHC, cho-
lesterol and plasma 24OHC and lanosterol (CV 5%, LOD
0.2 ng/ml) were measured by gas chromatography isotope-
dilution mass spectrometry as in Leoni et al [9]. CSF and plasma
NfL (CV 5%, LOD 0.09 ng/ml) was measured according to
Figure 1. A diagrammatic representation of patient follow up and investigations. CSF sampling was performed at 6 and 18 m in 9 subjects
and 12 m in 14 subjects.
doi:10.1371/journal.pone.0070019.g001
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Kester et al [10]. NAA (CV 2%, LOD 0.01 mmol/l) was analysed
by gas chromatography-mass spectrometry (GM-CSF) method by
Jasperse et al [11]. CSF MBP was measured using ELISA kit
(#T994ZB31, Cosmic Corporation; CV 11%, LOD 0.03 ng/ml).
CSF ferritins, NCAM, GAP–43 were measured using in-house
ELISA’s (CV’s 7, 5, and 7% respectively, and LOD 0.30 ng/ml,
12.43 ng/ml, and 8.73 ng/ml respectively). CSF and plasma
GFAP and NfH were measured as above. Cytokines (IL12p70,
IFN-c, IL-2, IL-10, IL-8, IL-6, IL-4, IL-5, IL-1b, TNF-a, TNF- b)
were measured flow cytometry using FlowCytomix kit (Bender
Medsystems, CV 16%, LOD range 215.28 pg/ml to 1068 pg/ml
depending on the cytokine). CCL21 (#D6C00, R? CV 11%,
LOD 795.07 pg/ml), CXCL12 (#DSA00, R? CV 9%, LOD
69.74 pg/ml), BLC (DY801, R? CV 9%, LOD 4.91 pg/ml), and
CCL19 (DY361, R? CV 4%, LOD 112.73 pg/ml) were measured
using ELISA kits. Plasma osteopontin (OPN, #DOST00, R? CV
6%, LOD 0.61 ng/ml) and DJ-1 (#CY-9050, CircuLex; CV 5%,
LOD 1.56 ng/ml) were measured using ELISA kits, and BDNF as
above.
Statistics
Changes in serum biomarkers NfH, NOx, GFAP, NGF and
BDNF between 0–12 m, 12–24 m and 0–24 m were calculated for
each patient. Differences in the distribution of changes between
lamotrigine and placebo and lamotrigine adherent and non-
adherent groups were determined by Kruskal-Wallis test. A
comparison of subjects getting better (reduction in NfH, NOx and
GFAP levels, and a rise in BDNF and NGF levels) were
determined by Chi-square test. To assess the relationships between
the serum biomarkers and the clinical and MRI measures the
levels were categorised. For NfH and GFAP three categories were
defined: absent (below assay detection), and above and below the
median of the detectable concentrations. For NOx, BDNF and
NGF four categories were defined bounded approximately by the
quartiles of each biomarker’s distribution (Table S1). Generalised
linear models were used to assess the relationships between the
categorised biomarkers and clinical and MRI measures. For each
clinical and MRI measure, least squares means for each level of
the biomarkers were obtained from the generalised linear model.
These means and their confidence levels were tabulated and
presented graphically. Walking times and 9-HPT times were log
transformed as their distributions were more symmetrical on a log
scale. Time to event analyses were conducted on walking times
and 9-HPT times, in which uncompleted tests were treated as
censored observations at 300 s. Survival curves of walking times
and 9-HPT times were produced. T1 and T2 lesion volumes were
also log transformed prior to analyses. All other clinical and MRI
measures were analysed in their original units.
Screening for relationships between the 31 biomarkers in CSF
and associated blood samples and clinical and MRI parameters
were carried out by tabulating the rank correlations between every
pair of variables. If a rank correlation suggested a statistically
significant relationship (p,0.05), it was examined in further detail.
Most serum immune markers were present in only few samples
and we therefore constructed single flag variable indicating the
presence of any serum immune biomarker.
Results
Treatment effect by comparing differences in NfH, NOx,
GFAP, BDNF and NGF values between the lamotrigine
and placebo groups
A summary table of serum biomarker values is in Table S1.
There were no significant differences in the values of the five
biomarkers between the two groups at 0–12 m, 12–24 m or 0–
24 m (p.0.05).
Treatment effect by comparing differences in NfH, NOx,
GFAP, BDNF and NGF values based on lamotrigine serum
adherence and tablet compliance
Reduction in NfH levels by measuring differences 0–12, 12–24
and 0–24 m between lamotrigine adherent and non-adherent
groups revealed significant differences between the two groups at
NfH 12–24 and NfH 0–24 m, p= 0.043 and p= 0.023, respec-
tively. This was further supported by measuring rate of change,
where lamotrigine adherent group showed a significant change
between 0–24 m in NfH levels (p = 0.041), with NfH levels at 12–
24 m having a p-value of 0.055. Grouping by improvement in
biomarker values (i.e. reduction in NfH) was significant in NfH 0–
24 m (p= 0.042). NOx, GFAP, BDNF and NGF values did not
differ between the two groups over time (p.0.05). Analysis based
on tablet returns did not reveal a significant difference in the
serum biomarker levels, except based on grouping by improve-
ment in biomarker levels for NfH 0–24 m (p= 0.012). However,
seven subjects who had been considered tablet compliant had
neither detectable serum lamotrigine levels or only at 6 m.
Relationship between NfH, NOx, GFAP, BDNF and NGF
values and clinical outcomes
NfH was found to be related to components of the MSFC. It
was a strong predictor of walking times, with patients having any
detectable NfH taking nearly twice as long to complete the test as
those with none (p,0.001; Figure 2a). The 9-HPT times using the
non-dominant hand were also longer in these patients, by 17% if
NfH levels were present but below the median and by 32% if it
was above the median (p,0.001; Figure 2c). This relationship
between test times and NfH levels was confirmed by time to event
analyses. Figure 3 shows the cumulative proportions of patients
completing each test plotted against time. Results using the
dominant hand revealed an increase of approximately 10% in 9-
hole peg test times, although this was not found to be statistically
significant (p.0.05; Figure 2b). The PASAT performance and z-
score values decreased with increasing NfH levels (Figure 2d, e).
NOx, GFAP and NGF were not found to be associated with the
timed walk, 9-hole peg test time or z-scores. However, patients
with high levels of NfH and BDNF had lower PASAT scores
(Figure 2d).
EDSS was higher in patients with detectable NfH, and there
was some indication of an association with NOx levels (Figure 2f).
MSIS-29 psychological but not physical scores were found to be
high in patients with higher BDNF levels, and there was some
evidence that they were higher in patients with NfH levels above
the median (Figure 2g, h). There was no correlation between
EDSS and MSIS-29 physical scores, and the other serum
biomarkers.
Figure 2. The relationship between serum biomarkers NfH,
NOx, GFAP, BDNF, NGF and clinical (MSFC, EDSS, MSIS-29) as
well as MRI measures are presented in tabular form and as
forest plots. a) 25-foot walk (secs); b) 9-hole peg test, dominant had
(secs); c) 9-hole peg test, non-dominant hand (secs); d) Paced Auditory
Serial Addition Test (PASAT); e) Z-score; f) Expanded Disability Status
Scale (EDSS); g) Multiple Sclerosis Impact Scale (MSIS-29) physical; h)
MSIS-29 psychological; i) Magnetization Transfer Ratio (MTR) white
matter; j) MTR grey matter; k) MTR whole brain; l) MRI Central Cerebral
Volume (MRICCV); m) T1 volume; n) T2 volume.
doi:10.1371/journal.pone.0070019.g002
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Relationship between NfH, NOx, GFAP, BDNF and NGF
values and MRI outcomes
Higher NfH was associated with lower MTR means in grey
matter, white matter and whole brain (Figure 2i, j, k). BDNF in the
highest quartile was also associated with lower MTR means, but
there was no correlation with NOx, GFAP or NGF levels.
MRICCV was highly correlated with all five serum biomarkers
(Figure 2l). It was higher in patients with higher levels of NOx and
GFAP and lower in patients with higher levels of NfH, BDNF and
NGF. There was no clear correlation between SCCA and any
biomarker (not shown).
T1 and T2 lesion volumes were higher in patients with higher
levels of BDNF and NGF (Figure 2 m, n).
Relationship between the CSF and blood biomarkers and
clinical outcomes
CSF biomarker analysis are summarised in Table S1. The rank
correlations are shown in Table S2. Although many of these
correlations were statistically significant, examination of the scatter
plots did not demonstrate a consistent trend aside from plasma
osteopontin. Higher plasma osteopontin values were associated
with lower MSFC z-score, MRICCV, and grey matter and whole
brain MTR (Figure S1). Non-parametric two sample tests based
on the presence or absence of any serum markers of immune
system activation also failed to reveal a difference for any clinical
parameter.
Discussion
We report on the prognostic value of serum neurofilament
measurement in neuroprotective clinical trials. The primary
hypothesis that lamotrigine will significantly reduce the proportion
of cases with detectable NfH in sera at 12 and 24 months relative
to baseline, compared to placebo was not evident in the intention
to treat group, although the true effect of Lamotrigine may have
been diluted by the low levels of compliance (40–50% non-
adherence based on return of tablets and serum lamotrigine
concentrations). Per protocol analysis based on serum and tablet
adherence was therefore also performed, which also tested the
pure pharmaceutical effect of the treatment. There was significant
reduction in serum NfH of subjects with detectable serum
lamotrigine between 12–24 m and 0–24 m, suggesting a possible
neuroprotective effect on axons by lamotrigine. The delay in the
reduction of NfH by 12 months implies a lead-lag effect between
taking the drug and neuroprotection. Lim et al. [12] demonstrated
that elevation in NfH between 0–3 weeks was predictive of poor
clinical outcome at week 8. We did not see a difference in serum
biomarker levels based on intention to treat analysis, nor did we
note a difference based on tablet returns; apart from NfH levels
between 0–24 m when comparing percentage of subjects ‘‘getting
better’’ on lamotrigine. Using tablet returns as a way of assessing
treatment compliance is prone to errors in judgment as
demonstrated, whilst serum drug levels are probably the closest
way to reliably assessing compliance. The original reports of this
trial based on MRI cerebral volumes did not support a
neuroprotective effect of lamotrigine, but this may have been
confounded by fluctuations in parenchymal water content from
sodium channel blockade, as indicated by partial improvement
upon treatment discontinuation [6].
NfH was a strong predictor of ambulation and disability based
on MSFC and EDSS, supporting the use of NfH as a surrogate
measure of disability. This is confirmed by the time-to-event
Figure 3. Survival curves of walking times and 9-hole peg test times (dominant and non-dominant hand) are plotted according to
absent, below median or above median NfH levels.
doi:10.1371/journal.pone.0070019.g003
Figure 4. Power curves for determining sample size for changes percentage change in NfH levels.
doi:10.1371/journal.pone.0070019.g004
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modelling for completion of the timed 25-foot walk. Interestingly,
performance in the 9-HPT and its relationship with NfH levels
was found predominantly in the non-dominant hand which may
be related to the loss in manual dexterity that may be more
obvious with the non-dominant hand as the test is normally
performed faster using the dominant hand [13]. Others have also
shown that high NfH levels correlate with poor visual outcome
[14,15]. Neuropsychological test scores from the PASAT and
MSIS-29 appeared to be also responsive to changes in NfH, with
patients with higher NfH having lower PASAT scores and higher
MSIS-29 psychological scores, possibly related to the significant
neurodegenerative changes observed in grey matter disease [16] or
in relation to EDSS deterioration, respectively; McGuigan et al.
found that MSIS-29 increased with EDSS deterioration [17].
NfH correlated well with all MRI-derived measures except for
conventional T1 and T2 volumes. MRICCV and MTR were both
lowered in patients with higher NfH, supporting earlier associa-
tions of NfH with clinical measures and connecting progressive
brain atrophy in SPMS to NfH release and a reduction in cerebral
volumes (MRICCV) and global disease burden (MTR). Our
observed lack of correlation between spinal cord area and NfH
levels may have been partly confounded by the lack of sensitivity of
spinal cord MR imaging to axonal disease [18].
Based on the parameters obtained for NfH we have estimated
the sample sizes that future studies would need to detect changes in
the proportion of patients with detectable NfH. In this study 80%
of samples had detectable NfH and we calculated the sample sizes
required to detect differences between this and 50, 55, 60, 65 and
70% in a comparator group (Figure 4).
We also analysed serum NOx, GFAP, BDNF and NGF, but
found significant association was between walking times or 9-HPT
times. However, MRI central cerebral volumes highly correlated
with NOx and GFAP as expected since inflammation and oedema
may increase brain volume. Cheriyan J et al. [19] noted transient
increases in brain volume during periods of MRI gadolinium
activity. Unexpectedly, high BDNF and NGF were associated with
lower MRI CCV and higher T1 and T2 volumes, whilst BDNF
levels in the highest quartile were associated with lower MTR
means. This can be interpreted as either reactive neuroplasticity
with upregulation of neurotrophins following injury, or as markers
of inflammation, as both have been shown to play a regulatory role
in inflammation [20]. Similarly, patients with higher BDNF, but
not NGF levels were found to have lower PASAT scores. More
work is needed in order to better understand the functional and
clinical implications of these findings.
Of the 31 paired CSF/serum/plasma biomarkers studied, no
clear trends emerged from the analyses aside from plasma
osteopontin (Figure S1). Higher levels of osteopontin have
previously been associated with greater disability, and our analysis
supports this with subjects exhibiting z-scores below average on
the MSFC, as well as reduced MRICCV and grey matter MTR
values [21]. The lack of association with the other biomarkers is
most likely secondary to the low statistical power. Correction for
multiple comparisons was not performed at this stage as the work
is exploratory in nature and positive findings should be tested in
future prospective studies. However, as a collaborative study with
John Hopkins University the CSF samples were analysed using
mass spectrometry based on serum drug adherence [22], which
revealed a significant reduction in 11 protein biomarkers,
including neurofilament.
In conclusion, the results of this study failed to show any benefit
of lamotrigine in the prevention of axonal breakdown by lowering
NfH levels compared to the placebo arm. A further subgroup
analysis based on lamotrigine adherence, however, suggests that it
may have a beneficial effect on axonal protection and it would be
premature to abandon this hypothesis in entirety. We have
demonstrated that NfH is very good surrogate marker of
neurodegeneration and correlates well with clinical and MRI
biomarkers of progression. The sample size calculations provided
in this paper should pave the way for neuroprotection trials using
serum NfH.
Supporting Information
Figure S1 Plasma osteopontin and its relationship with
the z-score, MRICCV, MTR grey matter and whole
brain are presented.
(TIF)
Table S1 Biomarker values in serum, plasma and CSF
samples from the lamotrigine trial. They are grouped
approximately by the quartiles of each biomarker’s distribution,
and in analysis where only a few were detectable as absolute
values.
(TIF)
Table S2 Rank correlation coefficients between bio-
markers and test scores (a) and MRI measures.
Statistically significant correlations (absolute values .0.346) are
shaded, red for positive correlations and green for negative.
(TIF)
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